Research & Development
Policy & Regulation
Trends & Finance
Financial Results: Page 2
Bio-Rad Laboratories Q3 revenues down 9% but beat analysts’ average estimate
For the quarter ended September 30, COVID-related revenue was approximately $17 million compared to $57 million in the year-ago period.
October 28, 2022
Labcorp Q3 revenues drop 11% on decline in COVID-19 testing
An almost 12% year-over-year decrease in COVID-19 PCR and antibody testing was partly offset by a 1.1% increase in Labcorp’s organic base business.
October 27, 2022
Thermo Fisher Scientific Q3 revenues rise 14% on strength in laboratory products, biopharma services
In Q3, the firm’s Laboratory Products and Biopharma Services segment revenues were $5.59 billion, up 60% year-over-year compared to $3.49 billion.
October 26, 2022
BioMérieux Q3 sales rise 3% with higher-than-expected respiratory test demand
In the third quarter, the France-based firm saw higher-than-expected demand for its BioFire molecular diagnostic respiratory panels for COVID-19 and other testing.
October 26, 2022
Danaher Q3 diagnostics revenues rise 9%
Third-quarter year-over-year core revenue growth within diagnostics was 14%, with Cepheid growing about 30%.
October 20, 2022
Quest Diagnostics Q3 revenues drop 10% on COVID testing decline
The Secaucus, NJ-based firm beat analysts’ average estimate for Q3 revenues of $2.35 billion and its shares rose in early Thursday trading on the NYSE.
October 20, 2022
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
C2N Diagnostics launching next-generation blood test for Alzheimer's disease detection
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Aspira announces commercial launch of blood-based ovarian cancer risk assay
Sherlock Biosciences secures funding to further develop CRISPR testing platform
Abbott Q3 diagnostics revenues decline 6% on lower COVID testing demand
Excluding COVID-19 testing-related sales, worldwide Diagnostics sales declined 0.2% on a reported basis and increased 6.1% on an organic basis in the third quarter.
October 19, 2022
QuidelOrtho expects Q3 revenues of $782 million to $785 million
For its first full quarter as a combined company, QuidelOrtho’s COVID-19 product revenue is expected to be approximately $171 million
October 12, 2022
Mainz posts drop in revenue, spike in net loss for H1
For the first half ended June 30, Mainz reported $239,805 in revenues compared to $417,311 in the same period in 2021.
September 6, 2022
Immunovia reports Q2 financial results
The firm posted a Q2 net loss of SEK 33.7 million, or a loss of SEK 1.49 per share.
August 23, 2022
LumiraDx Q2 revenues down 49% on drop in COVID testing
For the second quarter ended June 30, the London-based firm posted revenues of $44.7 million, compared to revenues of $87.2 million in Q2 2021, short of Wall Street analysts' average estimate of $53.1 million.
August 17, 2022
Agilent Technologies Q3 revenues rise 8%
For the fiscal third quarter ended July 31, Agilent's Life Sciences and Applied Markets Group posted revenues of $1.02 billion, a year-over-year increase of 14%; the CrossLab Group posted revenues of $359 million, a year-over-year increase of 5%; and the Diagnostics and Genomics Group posted revenues of $340 million, a year-over-year decrease of 2%.
August 16, 2022
Page 2 of 8